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Abstract: Glucocorticoid effect on thyrotropin-releasing hormone
(TRH)-induced prolactin (PRL) release was studied in female patients
with collagen or autoimmune diseases. Long-term, high dose gluco-
corticoid therapy tended to inhibit the response of plasma PRL to
TRH. A negative correlation (r = -0.40) was found between the loga-
rithm of total dose of glucocorticoids received and the magnitude of
plasma PRL response to TRH (p<.05).
Glucocorticoids have been known to inhibit the secretion of adrenocor-
ticotropic hormone (ACTH), growth hormone (GH) and thyroid stimulating
hormone (TSH) (1-5); however, not much is known about the effect of
glucocorticoids on prolactin (PRL) secretion.
The release of TSH stimulated by the administration of synthetic thyro-
tropin-releasing hormone (TRH) is sensitive to inhibition by natural and
synthetic glucocorticoids (6). We have previously investigated the effect of
glucocorticoids on the secretion of prolactin- utilizing synthetic TRH, which
stimulates PRL release by direct action on the pituitary (8). In the present
study, the PRL response to synthetic TRH was determined on female patients
receiving glucocorticoids.
MATERIALS AND METHODS
The subjects were 10 normal females and 29 female patients with collagen
diseases or autoimmune diseases. They patients were examined before and
during glucocorticoid (GC) therapy.
All tests were begun at 9 a.m. after an overnight fast. After I ml of blood
sample was drawn for control purposes, 500 flg of synthetic TRH (Tanabe
Seiyaku Co., Ltd.) was injected intravenously. Additional blood sampl~s were
drawn at 15,30,45,60 and 90 min after injection of TRH. The plasmas were
immediately separated after each blood collection and frozen until PRL assay.
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The dose of glucocorticoids (GC) was calculated at the prednisolone equiv-
alent. Patients received GC at the equivalent dose just after injection of
TRH.
The maximum increment of plasma PRL above the basal level after TRH
administration was used as the index of PRL response to TRH. Plasma PRL
was measured by the radioimmunoassay kit that was kindly supplied by the
National Institute of Arthritis, Metabolism, and Digestive Diseases, U S.A. (9).
RESULTS
No significant difference was present between basal PRL levels in
normal females and in glucocorticoid-treated patients. Fig. I shows the
plasma PRL response of patients with collagen diseases or autoimmune
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Fig. 1. Plasma prolactin responses to TRH in normal females and in female
patients with collagen diseases or autoimmune diseases before and during gluco-
corticoids treatment. NS, not significant.
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diseases to 500 fig TRH before and during glucocorticoid treatment. In
patients on high doses of glucocorticoids (more than 1,000 mg of prednisolone
equivalent) the plasma PRL response to TRH was slightly inhibited.
The decrease in PRL response to TRH after glucocorticoid treatment
was examined further in glucocorticoid-treated patients, as shown in Fig. 2.
The correlation coefficient between the magnitude of the logarithm of the
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Fig. 2. Correlation between the magnitude of the plasma prolactin response to TRH
and the total dn~~ of glucocorticoid received, in patients.
W, wcek(s); M, month(s); Y, year
total dose of glucocorticoid received and the plasma PRL response was
-DAD (p<.05).
DISCUSSION
The effect of glucocorticoids on human PRL secretion remains obscure,
although PRL secretion has been examined extensively in recent years. The
availability of synthetic TRH enables investigatons of the effect of gluco-
corticoids on the secretion of PRL from the anterior pituitary.
It is known that most patients with Cushing's syndrome show impaired
TSH response to TRH (6, 8). We have previously reported that two out of
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seven patients with Cushing's syndrome showed subnormal PRL responses to
TRH before adrenalectomy, although these patients responded normally after
adrenalectomy (9). Therefore, it is possible that the natural glucocorticoid
cortisol could inhibit PRL secretion at the pituitary level.
In the present study, TRH-induced PRL secretion tended to be impaired
in patients receiving long-term, high doses of synthetic glucocorticoids.
Almost all such patients showed impaired TSH response to TRH (10).
Thus, glucocorticoids inhibit both TRH-induced PRL secretion and
TRH-induced TSH secretion. However, the degree of suppression by
glucocorticoids of PRL secretion was less than that of TSH secretion.
Acknowledgment: We wish to thank the National Institute of Arthritis, Metabolism, and
Digestive Diseases, U.S.A., for supplying the materials for human prolactin radioimmuno-
assay.
REFERENCES
1. Sayers, G., Redgate, E. S. and Royce, P. C.: Hypothalamus, adenohypophysis and
adrenal cortex. Annu. Rev. Physiol. 2(1, 243-274, 1958.
2. Frantz, A. G. and Babkin, M. T.: Human growth hormone. New Engl. J. Med. 271, 1375-
1381, 1964.
3. Hartog, M., Graafer, M. A. and Fraser, R.: Effect of corticosteroids on serum growth
hormone. Lancet 2, 376-379, 1964.
4. Willer, J.F. and Utiger, R.D.: The effect of glucocorticoids on thyrotropin secretion.
J. Clin. Invest. 48, 2096-2103, 1969.
5. Nicoloff, J. T., Fisher, D.A. and Appleman, Jr., M.D.: The role of glucocorticoids in
the regulation of thyroid function in man. J. Clin. Invest. 49, 1922-1929, 1970.
6. Otsuki, M., Sakoda, M. and Baba, S.: Influence of glucocorticoids on TRF-induced
TSH response in man. J. Clin. Endocrinol. Metab. 36,95-102, 1973.
7. Bowers, C. Y., Friesen, H., Hwang, P., Guyda, H. and Folkers, K.: Prolactin and thy-
rotropin release in man by synthetic tyroglutamyl-histidyl-prolinamide. Biochem. Biophys.
Res. Commun. 45, 1033-1041, 1971.
8. Hashimoto, K., Asaoka, K., Mori, M., Yokoyama, H., Miyoshi, M., Hosogi, H., Yozai,
S., Ogawa, N. and Ofuji, T.: The pituitary ACTH,GH,LH,FSH, TSH and prolactin
reserves in patients with Cushing's Syndrome. Folia Endocrinol. Jpn. 50, 537, 1974 (in
Japanese) .
9. Ogawa, N., Miyoshi, M., Suzuki, S., Ofuji, T. aud Furuno, K.: Effects of synthetic
TRH on plasma human prolactin levels in normal subjects and in patients with various
endocrine disorders. Folia Endocrinol. Jpn. 50, 1300-1309, 1974 (in Japanese with English
abstract) .
10. Miyoshi, M., Takehisa, Y. and Suzuki, S.: Plasma TSH measurement by radioimmuno-
assay and its clinical application. Clin. Endocrinol. (Tokyo) 21, 1187-1191, 1973 (in Japa-
nese).
4
Acta Medica Okayama, Vol. 29 [1975], Iss. 5, Art. 3
http://escholarship.lib.okayama-u.ac.jp/amo/vol29/iss5/3
